A Kansas overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
37.6% of Kansas adults have obesity, per the CDC's 2024 BRFSS data 4 — well above the 33.1% national rate from the same dataset 5. Kansas is home to 2,970,606 residents (Census Vintage 2024) 6.
Most state pages here have to explain an exclusion. Kansas gets to explain a benefit that widened in 2025.
Yes, with prior authorization. Kansas Medicaid (KMAP), delivered through KanCare managed care, covers all three branded GLP-1 anti-obesity medications — Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) — for weight management. Standard PA requires a BMI of 30+, or 27+ with a qualifying comorbidity (type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, NASH, PCOS, obstructive sleep apnea, and others), documented lifestyle intervention, and a prescriber-reported baseline weight/BMI 1.
As of June 1, 2025, Wegovy moved off the stricter high-cost tier that Zepbound had already left on April 1, 2024 — both drugs now qualify under the standard obesity-BMI criteria above rather than the harder severe-obesity (BMI 40+) gate 1. Initial approval runs 28 weeks; renewal requires 5% weight loss maintained at 12 weeks or 10% at 28 weeks.
Seven older-generation weight-loss drugs (phentermine, phentermine/topiramate, naltrexone/bupropion, orlistat, diethylpropion, phendimetrazine, benzphetamine) are covered with no PA at all 123. KanCare MCO formularies were not independently checked for this page; state rule requires MCOs be no more restrictive than the fee-for-service list, but plan-level PA forms remain unverified.
Coverage helps the members who clear the PA criteria. Everyone else in Kansas is comparing cash prices.
Astra's price in Kansas is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. The number is the same in Wichita as everywhere else; there is no Kansas price list and no regional discount.
Median household income in Kansas is $75,514 and roughly 8.5% of residents are uninsured (ACS 2024 1-year estimates) 7.
TODO before publish: Kansas-specific telehealth-prescribing and compounded-GLP-1 dispensing rules have not been verified against a primary source. Compounded-drug rules are set by state pharmacy boards and have been shifting through 2025–2026. Attempted verification of the Kansas State Board of Pharmacy site on 2026-08-28 returned HTTP 403 to automated fetch — consistent with bot-protection, not evidence the page is down. Confirm in a browser and pull the actual rule text before asserting anything state-specific.
Astra is licensed to treat patients in Kansas and in all 50 states.
Astra treats patients in Kansas through state-licensed physicians.
Wichita is home to 400,993 people, roughly 13.5% of the state's population [8].
Yes, with prior authorization. KMAP covers Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) for weight management for members with a BMI of 30+, or 27+ with a qualifying condition such as type 2 diabetes or hypertension, plus documented lifestyle intervention. Source: KDHE/KMAP Anti-Obesity Medications PA criteria.
No — deliberately. Astra is a telehealth provider, not a local clinic, so the price is identical everywhere: $68/month for semaglutide and $118/month for tirzepatide on a 12-month plan ($816 / $1,416 billed annually), the same in Wichita as in every other city Astra serves.
Not the branded GLP-1s. Only seven older-generation weight-loss drugs — phentermine, phentermine/topiramate, naltrexone/bupropion, orlistat, diethylpropion, phendimetrazine, and benzphetamine — are covered by KMAP with no PA required. Wegovy, Zepbound, and Saxenda all require prior authorization.
No — Astra's care model is entirely telehealth. [TODO: confirm the specific Kansas Board of Pharmacy / medical board rule on telehealth prescribing and compounded GLP-1 dispensing before publishing; do not assert a rule not yet verified.]
Yes. Astra is licensed to treat patients in all 50 states, including every city and county in Kansas — Wichita, Overland Park, Kansas City KS, Topeka, and beyond.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.